Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

In case you missed it, this week we had news about tapinarof’s FDA approval in AD patients 2 and older, new ICD-10 codes for CCCA and FFA, a phase 2 study of INF904, and more.

The Weekly Roundup: December 16-20

Renata Block, MMS, PA-C; Ted Lain, MD, MBA, FAAD; Zoe Diana Draelos, MD; and Cheri Frey, MD, FAAD, bust common skin care myths in a Dermatology Times custom video series.

Dispelling Skin Myths: A New Era of Preventative Care for Anti-Aging, Cleansing, and Sunscreen

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Dermatology Times is looking back on the top stories in dermatology from the month of December.

Dermatology Times December 2024 Recap

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

The company stated INF904 disrupts inflammatory pathways with over 90% effectiveness, based on Phase 1 data.

InflaRx Advances INF904 for CSU and HS with Phase 2a Study

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

View

Beyond the Stigma: Patient Stories in Vitiligo Management

Balancing Vitiligo Treatments with Coverage Challenges

Videos

various aspects of vitiligo management through case-based discussions and insights including navigating emotional and clinical challenges to balancing treatment options with coverage constraints.

Ted Lain, MD, MBA, FAAD offers insights into navigating the emotional and clinical challenges in vitiligo management. 

Insights into Navigating the Emotional and Clinical Challenges in Vitiligo Management

Ted Lain, MD, MBA, FAAD discusses balancing vitiligo treatments with coverage challenges.

Ted Lain, MD, MBA, FAAD discusses a case which addresses location-specific concerns and treatment challenges in vitiligo management. 

Case-Based Insights: Addressing Location-Specific Concerns and Treatment Challenges in Vitiligo Management

Ted Lain, MD, MBA, FAAD discusses navigating the treatment paradigm for vitiligo. 

Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib

Case Based Peer Perspectives

Balancing Vitiligo Treatments with Coverage Challenges

EP: 1.Insights into Navigating the Emotional and Clinical Challenges in Vitiligo Management

EP: 2.Balancing Vitiligo Treatments with Coverage Challenges

EP: 3.Case-Based Insights: Addressing Location-Specific Concerns and Treatment Challenges in Vitiligo Management

EP: 4.Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib